Suppr超能文献

一种用于药物发现中化学先导物鉴定和评估的多步核磁共振筛选方法。

A multi-step NMR screen for the identification and evaluation of chemical leads for drug discovery.

作者信息

Mercier Kelly A, Shortridge Matthew D, Powers Robert

机构信息

Department of Chemistry, University of Nebraska-Lincoln, Lincoln, NE 68588, USA.

出版信息

Comb Chem High Throughput Screen. 2009 Mar;12(3):285-95. doi: 10.2174/138620709787581738.

Abstract

A multi-step NMR based screening assay is described for identifying and evaluating chemical leads for their ability to bind a target protein. The multi-step NMR assay provides structure-related information while being an integral part of a structure based drug discovery and design program. The fundamental principle of the multi-step NMR assay is to combine distinct 1D and 2D NMR techniques, in such a manner, that the inherent strengths and weakness associated with each technique is complementary to each other in the screen. By taking advantage of the combined strengths of 1D and 2D NMR experiments, it is possible to minimize protein requirements and experiment time and differentiate between non-specific and stoichiometric binders while being able to verify ligand binding, determine a semi-quantitative dissociation constant, identify the ligand binding site and rapidly determine a protein-ligand co-structure. Furthermore, the quality and physical behavior of the ligand is readily evaluated to determine its appropriateness as a chemical lead. The utility of the multi-step NMR assay is demonstrated with the use of PrgI from Salmonella typhimurium and human serum albumin (HSA) as target proteins.

摘要

本文描述了一种基于核磁共振(NMR)的多步筛选测定法,用于鉴定和评估化学先导物与目标蛋白的结合能力。这种多步NMR测定法在提供与结构相关信息的同时,也是基于结构的药物发现与设计计划的一个组成部分。多步NMR测定法的基本原理是将不同的一维(1D)和二维(2D)NMR技术以这样一种方式结合起来,即每种技术所固有的优势和劣势在筛选过程中相互补充。通过利用1D和2D NMR实验的综合优势,可以将蛋白质需求量和实验时间降至最低,区分非特异性结合物和化学计量结合物,同时能够验证配体结合、确定半定量解离常数、识别配体结合位点并快速确定蛋白质-配体共结构。此外,还可以很容易地评估配体的质量和物理行为,以确定其作为化学先导物的适用性。以鼠伤寒沙门氏菌的PrgI和人血清白蛋白(HSA)作为目标蛋白,证明了多步NMR测定法的实用性。

相似文献

1
A multi-step NMR screen for the identification and evaluation of chemical leads for drug discovery.
Comb Chem High Throughput Screen. 2009 Mar;12(3):285-95. doi: 10.2174/138620709787581738.
2
Estimating protein-ligand binding affinity using high-throughput screening by NMR.
J Comb Chem. 2008 Nov-Dec;10(6):948-58. doi: 10.1021/cc800122m. Epub 2008 Oct 3.
3
Use of 19F NMR spectroscopy to screen chemical libraries for ligands that bind to proteins.
Org Biomol Chem. 2004 Mar 7;2(5):725-31. doi: 10.1039/b313166a. Epub 2004 Feb 3.
5
Ligand-based nuclear magnetic resonance screening techniques.
Methods Mol Biol. 2009;572:81-100. doi: 10.1007/978-1-60761-244-5_6.
6
Application of NMR and molecular docking in structure-based drug discovery.
Top Curr Chem. 2012;326:1-34. doi: 10.1007/128_2011_213.
7
[NMR screening in fragment-based drug discovery].
Yakugaku Zasshi. 2010 Mar;130(3):325-33. doi: 10.1248/yakushi.130.325.
9
NMR techniques for characterization of ligand binding: utility for lead generation and optimization in drug discovery.
Biopolymers. 1999;51(3):221-43. doi: 10.1002/(SICI)1097-0282(1999)51:3<221::AID-BIP5>3.0.CO;2-9.
10
Competition STD NMR for the detection of high-affinity ligands and NMR-based screening.
Magn Reson Chem. 2004 Jun;42(6):485-9. doi: 10.1002/mrc.1381.

引用本文的文献

1
Fragment-Based Approaches to Identify RNA Binders.
J Med Chem. 2023 May 25;66(10):6523-6541. doi: 10.1021/acs.jmedchem.3c00034. Epub 2023 May 15.
2
Leveraging the Structure of DNAJA1 to Discover Novel Potential Pancreatic Cancer Therapies.
Biomolecules. 2022 Sep 29;12(10):1391. doi: 10.3390/biom12101391.
3
Fragment-Based Drug Discovery by NMR. Where Are the Successes and Where can It Be Improved?
Front Mol Biosci. 2022 Feb 18;9:834453. doi: 10.3389/fmolb.2022.834453. eCollection 2022.
5
NMR Metabolomics Protocols for Drug Discovery.
Methods Mol Biol. 2019;2037:265-311. doi: 10.1007/978-1-4939-9690-2_16.
6
Statistical removal of background signals from high-throughput (1)H NMR line-broadening ligand-affinity screens.
J Biomol NMR. 2015 Sep;63(1):53-8. doi: 10.1007/s10858-015-9962-3. Epub 2015 Jul 9.
7
NMR Metabolomics Analysis of Parkinson's Disease.
Curr Metabolomics. 2013;1(3):191-209. doi: 10.2174/2213235X113019990004.
9
Application of NMR and molecular docking in structure-based drug discovery.
Top Curr Chem. 2012;326:1-34. doi: 10.1007/128_2011_213.
10
Research in bioanalysis and separations at the University of Nebraska - Lincoln.
Bioanalysis. 2011 May;3(10):1065-76. doi: 10.4155/bio.11.64.

本文引用的文献

1
Characterization of Ligand Binding by Saturation Transfer Difference NMR Spectroscopy.
Angew Chem Int Ed Engl. 1999 Jun 14;38(12):1784-1788. doi: 10.1002/(SICI)1521-3773(19990614)38:12<1784::AID-ANIE1784>3.0.CO;2-Q.
2
Fragment-based drug discovery using the SHAPES method.
Expert Opin Drug Discov. 2007 Dec;2(12):1555-66. doi: 10.1517/17460441.2.12.1555.
3
High resolution NMR for screening ligand/protein binding.
Curr Opin Drug Discov Devel. 1999 Jul;2(4):396-400.
4
Estimating protein-ligand binding affinity using high-throughput screening by NMR.
J Comb Chem. 2008 Nov-Dec;10(6):948-58. doi: 10.1021/cc800122m. Epub 2008 Oct 3.
5
Rapid protein-ligand costructures using chemical shift perturbations.
J Am Chem Soc. 2008 Jan 16;130(2):535-45. doi: 10.1021/ja0737974. Epub 2007 Dec 19.
6
Fluorescence spectroscopic and (19)f NMR studies of human thymidylate synthase with its cognate RNA.
J Biomol Struct Dyn. 2007 Dec;25(3):253-70. doi: 10.1080/07391102.2007.10507174.
8
Molecular recognition and screening using a 15N group selective STD NMR method.
J Am Chem Soc. 2007 Sep 19;129(37):11579-82. doi: 10.1021/ja073291l. Epub 2007 Aug 28.
9
Perspectives of biomolecular NMR in drug discovery: the blessing and curse of versatility.
J Biomol NMR. 2007 Oct;39(2):87-90. doi: 10.1007/s10858-007-9183-5. Epub 2007 Aug 15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验